Trials
Search / Trial NCT06444022

hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · May 29, 2024

Trial Information

Current as of February 19, 2025

Not yet recruiting

Keywords

H Aes Cs

ClinConnect Summary

This study is a controlled trial, with 18 subjects enrolled in the experimental group or the control group. The study will consist of four phases, including screening phase, preparation phase, hAESCs treatment phase and observational follow-up period. The cell dose of the experimental group was 1x10\^6 cells/kg and the control group is infused placebo (the composition was the same as hAESCs injection excipients, but did not contain hAESCs). The infusion of hAESCs/placebo at the day before HSCT and 7th days after HSCT.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Standard risk GVHD patients with hematological malignancies older than 18 years;
  • High risk GVHD patients with hematological malignancies: haplotype hematopoietic stem cell transplantation patients, donor is female or more than 30 years old;
  • Well informed about this study and signed a consent form before the trial;
  • Left ventricular ejection fraction (LVEF) ≧ 50%, no evidence of pericardial effusion;
  • No evidence of lung infection by X-rays examination;
  • Eastern cooperative oncology group (ECOG) performance status of 0 or 1, Hematopoietic cell transplantation - specific comorbidity index (HCT-CI) of 0, 1, 2;
  • Normal liver and kidney function: Serum bilirubin≤35µmol/L, AST/ALT was less than 2 times the upper limit of normal value, and serum creatinine ≤130µmol/L
  • Exclusion Criteria:
  • Reduce pretreatment dose or secondary transplantation;
  • Participate other clinical trials within 2 months before this study;
  • Female, 1) pregnant/nursing period, or 2) have a pregnancy plan during the study period, or 3) have fertility and cannot take effective contraception;
  • History of severe allergic disease or is allergic to one or more drugs;
  • Patients who are considered unsuitable for the study by the investigator.

Trial Officials

Xiaojun Huang

Study Chair

Nanfang Hospital, Southern Medical University

About Nanfang Hospital, Southern Medical University

Nanfang Hospital, affiliated with Southern Medical University, is a leading medical institution in China renowned for its comprehensive clinical services and commitment to advancing healthcare through research and education. As a clinical trial sponsor, Nanfang Hospital leverages its state-of-the-art facilities and a multidisciplinary team of expert researchers to conduct innovative studies aimed at improving patient outcomes and contributing to the global medical community. The hospital's focus on ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and scientific rigor.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0